Affinage

IL18BP

Interleukin-18-binding protein · UniProt O95998

Length
194 aa
Mass
21.1 kDa
Annotated
2026-04-28
52 papers in source corpus 19 papers cited in narrative 19 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

IL-18BP is a secreted high-affinity decoy receptor that neutralizes IL-18 by forming a 1:1 complex (Kd ~400 pM) with an extremely slow dissociation rate, thereby preventing IL-18 from engaging IL-18Rα/IL-18Rβ and blocking downstream MyD88–IRAK–TRAF6–NF-κB signaling and IFN-γ production (PMID:11497494, PMID:36496012). Its transcription is induced by IFN-γ via direct STAT1 binding to a proximal GAS element in the IL-18BP promoter, creating a negative feedback loop, with cell-type-specific modulation by CpG methylation at a single site adjacent to the GAS element that silences expression in monocytes but not epithelial cells (PMID:19046253, PMID:29409936). Homozygous loss-of-function mutations in IL18BP cause fulminant viral hepatitis through unrestrained IL-18-driven NK cell killing of hepatocytes (PMID:31213488). In the tumor microenvironment, IL-18BP is upregulated as a secreted immune checkpoint that suppresses anti-tumor T and NK cell responses, an activity that can be overcome by decoy-resistant IL-18 variants or anti-IL-18BP antibodies that displace pre-complexed IL-18 (PMID:32581358, PMID:38592331).

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 1999 High

    The existence of a soluble, non-receptor antagonist of IL-18 was unknown; affinity purification from human urine identified IL-18BP as a novel secreted protein homologous to viral IL-18-binding proteins that potently neutralizes IL-18 in vitro and in vivo, establishing a new class of cytokine regulation.

    Evidence IL-18 ligand affinity chromatography of concentrated human urine, protein microsequencing, cDNA cloning, recombinant protein neutralization assays

    PMID:38455460

    Open questions at the time
    • Binding affinity and stoichiometry not yet quantified
    • Endogenous expression sites and regulation unknown
    • Mechanism of action at the receptor level unresolved
  2. 2001 High

    Quantitative binding parameters were established: IL-18BP forms a 1:1 complex with IL-18 at Kd ~400 pM with a very slow off-rate, and circulating levels rise ~10-fold in sepsis to sequester most free IL-18, resolving how the decoy functions stoichiometrically in vivo.

    Evidence Sandwich ELISA and electrochemiluminescence assay for IL-18BPa and IL-18 in healthy and sepsis sera, mass action law calculations

    PMID:11497494

    Open questions at the time
    • Structural basis for high-affinity binding not determined
    • Source tissues responsible for elevated circulating IL-18BP during inflammation unknown
  3. 2003 Medium

    The question of how IL-18BP is regulated during inflammation was addressed: LPS selectively induces IL-18BP but not IL-18 mRNA in liver, while IL-18BPa:Fc blocks LPS/IL-12-induced IFN-γ and MMP-9 from human blood, confirming IL-18BP as an endogenous brake on IL-18-mediated inflammation.

    Evidence Real-time PCR in rat liver after LPS, human whole blood culture with IL-18BPa:Fc and ELISA readout

    PMID:12788303 PMID:12907250

    Open questions at the time
    • Transcription factor(s) driving LPS-induced IL-18BP expression unidentified
    • In vivo pharmacokinetics of IL-18BPa:Fc not established
  4. 2008 High

    The transcriptional mechanism of IFN-γ-induced IL-18BP expression was dissected, showing that STAT1 binds directly to a proximal GAS element in the IL-18BP promoter independently of IRF-1, establishing the molecular basis for the IFN-γ–IL-18BP negative feedback loop.

    Evidence EMSA, ChIP for STAT1, promoter mutagenesis, siRNA knockdown in DLD-1 cells

    PMID:19046253

    Open questions at the time
    • Additional transcription factor cooperativity not fully explored
    • Whether this GAS-dependent mechanism operates identically across all cell types unclear
  5. 2018 High

    Cell-type-specific epigenetic gating of IL-18BP induction was revealed: CpG methylation at a single site adjacent to the GAS element recruits MeCP2 and represses H3K9 acetylation and RNA Pol II loading in monocytes but not epithelial cells, explaining why monocytes are refractory to IFN-γ-driven IL-18BP expression. Separately, hepatic IL-18BP transcription was shown to require both STAT1 and C/EBPβ.

    Evidence Bisulfite sequencing, 5-aza-dC treatment, MeCP2 binding assay, H3K9ac and Pol II ChIP in monocytic vs. epithelial cells; luciferase reporter, ChIP, and siRNA rescue in hepatocytes

    PMID:29409936 PMID:30089853

    Open questions at the time
    • Whether CpG methylation is dynamically altered during monocyte differentiation or activation untested
    • Full set of tissue-specific cofactors not catalogued
  6. 2019 High

    The first human disease caused by IL-18BP deficiency was identified: a homozygous 40-nt deletion abolishing IL-18BP function led to fulminant hepatitis A, with unchecked IL-18-driven NK cell killing of hepatocytes, establishing IL-18BP as essential for hepatic immune homeostasis.

    Evidence Whole-exome sequencing of affected individual, loss-of-function validation, in vitro NK cell cytotoxicity assay against human hepatocytes, liver immunohistochemistry

    PMID:31213488

    Open questions at the time
    • Whether other viral hepatitides are similarly gated by IL-18BP deficiency unknown
    • Contribution of other IL-18BP isoforms not assessed
  7. 2020 High

    IL-18BP was recognized as a tumor-associated immune checkpoint: tumors upregulate IL-18BP to neutralize IL-18 in the microenvironment, and a directed-evolution-derived decoy-resistant IL-18 (DR-18) bypasses IL-18BP, rescuing polyfunctional CD8+ T cells, reducing T cell exhaustion, and promoting NK cell maturation for anti-tumor immunity.

    Evidence Directed evolution of IL-18, multiple syngeneic mouse tumor models, flow cytometric T and NK cell phenotyping, transcriptional profiling

    PMID:32581358

    Open questions at the time
    • Mechanism by which tumors upregulate IL-18BP not defined
    • Whether DR-18 causes systemic inflammatory toxicity in long-term models unclear
  8. 2023 High

    The in vivo role of IL-18BP during infection was further refined: a 'decoy-to-the-decoy' IL-18 construct that sequesters IL-18BP without signaling enhances innate lymphoid cell and T cell responses during Toxoplasma gondii infection, while IL-18BP knockout mice develop macrophage activation syndrome-like liver inflammation that is rescued by recombinant IL-18BP.

    Evidence D2D and DR-18 constructs in mouse infection models with flow cytometry and parasite burden; IL-18BP KO mouse MAS model with APB-R3 pharmacological rescue

    PMID:36827187 PMID:37918054

    Open questions at the time
    • Whether the D2D approach is applicable to other IL-18BP-dominant disease settings untested
    • Long-term consequences of IL-18BP blockade on immune tolerance unknown
  9. 2024 High

    Therapeutic targeting of IL-18BP in tumors was validated: an anti-IL-18BP monoclonal antibody (COM503) displaces pre-complexed IL-18 and restores tumor-localized T and NK cell activation without systemic cytokine elevation, demonstrating that IL-18BP sequestration in the TME is the dominant mechanism suppressing anti-tumor IL-18 activity.

    Evidence Antibody displacement assay, T/NK cell activation in vitro, multiple syngeneic mouse tumor models, TME immune phenotyping, serum cytokine measurement

    PMID:38592331

    Open questions at the time
    • Efficacy in human tumors not yet demonstrated
    • Structural basis of antibody-mediated IL-18 displacement from IL-18BP unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis of the IL-18BP–IL-18 interaction at atomic resolution validated experimentally, the full catalogue of tissue- and disease-specific transcriptional and post-transcriptional regulators of IL-18BP, and whether IL-18BP has IL-18-independent functions.
  • No experimentally validated high-resolution structure of the human IL-18BP–IL-18 complex
  • Post-translational modifications and secretion mechanism of IL-18BP uncharacterized
  • Potential IL-18-independent roles of IL-18BP not investigated

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 5 GO:0140313 molecular sequestering activity 4
Localization
GO:0005576 extracellular region 5
Pathway
R-HSA-168256 Immune System 5 R-HSA-162582 Signal Transduction 4
Partners
CEBPBIL18MECP2STAT1

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 IL-18BP was originally discovered by subjecting concentrated human urine to an IL-18 ligand affinity column, revealing a novel soluble antagonist of IL-18 that shares homology with viral proteins and is distinct from the IL-18Rα and IL-18Rβ chains. Recombinant IL-18BP potently neutralizes IL-18 activity in vitro and in vivo. IL-18 ligand affinity chromatography, protein microsequencing, cDNA library screening, recombinant protein production, in vitro neutralization assays Immune network High 38455460
2001 IL-18BP forms a 1:1 high-affinity complex with IL-18 (Kd=400 pM) with a very low dissociation rate, effectively blocking IL-18 biological activity. Circulating IL-18BPa in healthy humans is ~2.15 ng/ml; in sepsis it rises to ~21.9 ng/ml, binding most circulating IL-18 and substantially reducing free IL-18. Sandwich ELISA for IL-18BPa, electrochemiluminescence assay for IL-18, mass action law calculation of free IL-18, serum measurements in healthy individuals and sepsis patients Cytokine High 11497494
2008 IFN-γ induces IL-18BP expression in DLD-1 colon carcinoma cells via direct binding of STAT1 to a proximal gamma-activated sequence (GAS) element in the IL-18BP promoter, establishing a negative feedback mechanism. IRF-1 is not required, and maximal expression requires de novo protein synthesis. Mutational analysis of IL-18BP promoter, siRNA knockdown of STAT1, electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP), actinomycin D treatment Journal of cellular and molecular medicine High 19046253
2018 Remifentanil upregulates hepatic IL-18BP expression through transcriptional activation of the IL-18BP promoter, requiring STAT1 and C/EBPβ as key transcription factors. The upregulated IL-18BP inhibits IL-18-activated NF-κB p65 phosphorylation in hepatocytes. qRT-PCR, Western blot, luciferase reporter assay, ChIP, siRNA knockdown of STAT1 and C/EBPβ, actinomycin D treatment, IL-18BP siRNA knockdown functional rescue Laboratory investigation High 30089853
2018 CpG methylation at a single CpG site (CpG2) neighboring the GAS element in the IL-18BP promoter epigenetically silences IFN-γ-induced IL-18BP expression in monocytic cells but not epithelial cells. Demethylation by 5-aza-2'-deoxycytidine impedes MeCP2 interaction with CpG2, increases adjacent histone H3K9-acetylation, and enhances RNA polymerase II recruitment to the IL-18BP transcriptional start site. 5-aza-2'-deoxycytidine treatment, bisulfite sequencing, promoter analysis, MeCP2 binding assay, histone H3K9 acetylation assay, RNA polymerase II ChIP Biochimica et biophysica acta. Gene regulatory mechanisms High 29409936
2019 Inherited human IL-18BP deficiency (homozygous 40-nucleotide deletion, loss-of-function) underlies fulminant hepatitis A virus hepatitis. Human IL-18 and IL-18BP are both secreted predominantly by hepatocytes and macrophages in the liver. In the absence of IL-18BP, excessive NK cell activation by IL-18 results in uncontrolled killing of human hepatocytes in vitro. Whole-exome sequencing, loss-of-function validation of the IL-18BP variant, in vitro NK cell killing assay of human hepatocytes, immunohistochemistry of liver The Journal of experimental medicine High 31213488
2020 IL-18BP is frequently upregulated in diverse human and mouse tumours (acting as a secreted immune checkpoint), limits the anti-tumour activity of IL-18, and can be overcome by engineering 'decoy-resistant' IL-18 (DR-18) that maintains IL-18 receptor signalling but is impervious to IL-18BP inhibition. DR-18 promotes poly-functional effector CD8+ T cells, reduces TOX-expressing exhausted CD8+ T cells, expands TCF1+ precursor CD8+ T cells, and enhances NK cell maturation. Directed evolution of IL-18, mouse tumour models, CD8+ T cell and NK cell phenotyping by flow cytometry, in vivo anti-tumour efficacy experiments, transcriptional profiling Nature High 32581358
2003 IL-18BPa:Fc fusion protein significantly inhibits LPS/IL-12-induced IFN-γ and MMP-9 release from human whole blood cultures and cooperates additively with immunosuppressive drugs (dexamethasone, mycophenolic acid) to further reduce IFN-γ production. Human whole blood culture assay, ELISA for IFN-γ and MMP-9, pharmacological combination experiments with immunosuppressive drugs Biochemical pharmacology Medium 12907250
2007 Porphyromonas gingivalis LPS induces both IL-18 and IL-18BPa secretion in human THP-1 monocytes. Addition of antibodies to IL-18BPa to stimulated cultures results in increased free IL-18, confirming specific IL-18/IL-18BPa interaction in this system. VIP (10⁻⁸M) inhibits both IL-18 and IL-18BP secretion. ELISA, neutralizing antibody blockade of IL-18BPa in THP-1 cell culture, VIP inhibition assay Journal of dental research Medium 17720860
2003 LPS selectively upregulates IL-18BP mRNA (~12-fold) but not IL-18 mRNA in rat liver within 3 hours, suggesting IL-18BP induction is a regulatory mechanism to control IL-18 activity during systemic inflammation. Real-time PCR measurement of IL-18BP and IL-18 mRNA in rat liver following peripheral LPS injection Cytokine Medium 12788303
2016 Bioinformatic and phylogenetic analysis reveals that IL-18BP is evolutionarily most similar to IL-1R9 (IL-1R accessory protein-like 2) across mammalian species, sharing conserved intron/exon boundaries, protein structure, and key binding site amino acids, suggesting IL-18BP and IL-1R9 share a common evolutionary origin and that IL-1R9 and IL-1R8 may bind IL-18. Bioinformatics database analysis (Ensembl, NCBI), phylogenetic analysis, protein structure comparison, binding site amino acid alignment across 86 species Journal of immunology Low 27881706
2023 MD simulations of all known IL-18–IL-18BP crystal complexes show that a short epitope of IL-18 (amino acids 68–81), which is disordered in IL-18–IL-18BP complexes but adopts a 3₁₀ helix in receptor complexes, stabilizes the IL-18BP heterodimer. C74 within this epitope can form an intermolecular disulfide bond in the self-assembled human IL-18–IL-18BP tetramer, contributing to complex stability. All-atom molecular dynamics simulations of PDB structures and computed complex models, analysis of intermolecular disulfide bond formation Computational and structural biotechnology journal Low 37484491
2023 IL-18BP functions as a decoy receptor that limits endogenous IL-18 activity during Toxoplasma gondii infection; antagonism of IL-18BP with a 'decoy-to-the-decoy' (D2D) IL-18 construct (which binds IL-18BP but does not signal) releases IL-18 and enhances innate lymphoid cell and T cell responses and parasite control, whereas IL-18BP-resistant DR-18 enhances CD4+ T cell IFN-γ but causes pathology. Mouse infection model, D2D IL-18 construct, DR-18 construct, flow cytometry, IFN-γ measurement, parasite burden quantification Cell reports High 36827187
2019 miR-92b-5p directly suppresses IL-18BP expression in microglia; transfection with miR-92b-5p decreases IL-18BP and increases IL-18 mRNA, while miR-92b-5p inhibitor reverses this. In a mouse spinal cord injury model, miR-92b-5p inhibitor intrathecal injection increases IL-18BP and reduces inflammatory mediators (iNOS, TNF-α, IL-1β), improving locomotor function. miRNA transfection and inhibitor treatment in microglia, qRT-PCR, Western blot, in vivo spinal cord injury model, intrathecal injection, Basso Mouse Scale locomotor evaluation European review for medical and pharmacological sciences Medium 30915731
2024 IL-18BP alleviates HSR-induced anxiety-like behavior in mice by inhibiting the IL-18R-NLRP3 signaling pathway in astrocytes, reducing astrocytic activation, cleaved caspase-1, GSDMD, and pyroptosis-associated factors; these effects are partially reversed by the NLRP3 agonist nigericin and are absent in astrocyte-specific NLRP3 knockout mice. Mouse hemorrhagic shock/resuscitation model, IL-18BP intraperitoneal injection, open-field and elevated plus maze behavioral tests, Western blot (caspase-1, GSDMD), immunofluorescence, astrocyte-specific NLRP3 KO mice, NLRP3 agonist nigericin rescue experiment Molecular neurobiology Medium 36269543
2024 Anti-IL-18BP monoclonal antibody (COM503) blocks the IL-18BP:IL-18 interaction and displaces pre-complexed IL-18, restoring free IL-18 activity and enhancing T- and NK-cell activation in vitro. In vivo, surrogate anti-IL-18BP induces tumor-localized immune modulation (increased polyfunctional non-exhausted T and NK cells) without systemic inflammatory cytokine elevation, demonstrating that IL-18BP sequestration in the TME is the primary mechanism suppressing IL-18. Anti-IL-18BP antibody generation, displacement assay for pre-complexed IL-18, T/NK cell activation in vitro assays, multiple syngeneic mouse tumor models, TME immune phenotyping by flow cytometry, serum cytokine measurement Cancer immunology research High 38592331
2022 In rainbow trout, recombinant IL-18BP functions as a decoy receptor that downregulates IL-18-induced NF-κB activation in HEK293T cells, demonstrating conserved inhibitory function. Co-IP assays showed IL-18Rβ forms a complex with MyD88, IRAK4, IRAK1, TRAF6, and TAB2, placing IL-18BP inhibition upstream of this signaling complex. Transfection of chimeric receptors in HEK293T cells, NF-κB reporter assay, co-immunoprecipitation Developmental and comparative immunology Medium 36496012
2023 IL-18BP (as APB-R3, an albumin-binding long-acting recombinant form) directly inactivates IL-18 and alleviates liver inflammation and splenomegaly in IL-18BP knockout mice with macrophage activation syndrome, and controls skin inflammation in atopic dermatitis, demonstrating that IL-18BP blockade of IL-18 is sufficient to suppress these inflammatory phenotypes. IL-18BP knockout mouse MAS model, APB-R3 treatment, liver and spleen pathology assessment, atopic dermatitis mouse model, pharmacokinetics measurement Cytokine Medium 37918054
2025 In Il18bp KO mice, NK cells become inert upon mousepox infection and fail to activate or expand, resulting in viremic MAS and poor viral clearance, demonstrating that IL-18BP is required for proper NK cell function during viral infection and that its absence leads to NK cell hypoactivation alongside CTL hyperactivation. Il18bp knockout mice, mousepox infection model, NK cell transfer rescue experiment, CTL expansion and viral clearance assays bioRxivpreprint Medium bio_10.1101_2025.07.04.663237

Source papers

Stage 0 corpus · 52 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2020 IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 289 32581358
2018 Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Annals of the rheumatic diseases 232 29472362
2001 A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 223 11497494
2014 Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. Journal of leukocyte biology 145 25548255
2019 Inherited IL-18BP deficiency in human fulminant viral hepatitis. The Journal of experimental medicine 91 31213488
2014 Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediators of inflammation 88 24733959
2010 Serum IL-18 and IL-18BP levels in patients with Chikungunya virus infection. Viral immunology 46 20121409
2009 Expression of interleukin-18, IL-18BP, and IL-18R in serum, synovial fluid, and synovial tissue in patients with rheumatoid arthritis. Clinical and experimental medicine 43 19225717
2014 Pressure overload induces IL-18 and IL-18R expression, but markedly suppresses IL-18BP expression in a rabbit model. IL-18 potentiates TNF-α-induced cardiomyocyte death. Journal of molecular and cellular cardiology 42 25108227
2023 Interleukin-18 and IL-18BP in inflammatory dermatological diseases. Frontiers in immunology 38 36742296
2007 Free Interleukin (IL)-18 levels, and the impact of IL18 and IL18BP genetic variation, in CHD patients and healthy men. Arteriosclerosis, thrombosis, and vascular biology 32 17951325
2012 Elevated levels of circulating IL-18BP and perturbed regulation of IL-18 in schizophrenia. Journal of neuroinflammation 29 22913567
2008 Molecular mechanisms of IL-18BP regulation in DLD-1 cells: pivotal direct action of the STAT1/GAS axis on the promoter level. Journal of cellular and molecular medicine 26 19046253
2020 Interleukin 18 (IL-18) and its binding protein (IL-18BP) are increased in patients with epilepsy suggesting low-grade systemic inflammation. Seizure 25 32659652
2020 IL-18 binding protein (IL-18BP) as a novel radiation countermeasure after radiation exposure in mice. Scientific reports 25 33122671
2019 MiR-92b-5p inhibitor suppresses IL-18 mediated inflammatory amplification after spinal cord injury via IL-18BP up-regulation. European review for medical and pharmacological sciences 23 30915731
2003 IL-18BPa:Fc cooperates with immunosuppressive drugs in human whole blood. Biochemical pharmacology 23 12907250
2024 IL-18 and IL-18BP: A Unique Dyad in Health and Disease. International journal of molecular sciences 22 39769266
2008 Interleukin 18 binding protein (IL18-BP) inhibits neointimal hyperplasia after balloon injury in an atherosclerotic rabbit model. Journal of vascular surgery 22 18455646
2017 Elevated IL-37, IL-18 and IL-18BP serum concentrations in patients with primary Sjögren's syndrome. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20 28057714
2024 Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects. Cancer immunology research 19 38592331
2023 Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition. mAbs 18 37469014
2007 VIP inhibits P. gingivalis LPS-induced IL-18 and IL-18BPa in monocytes. Journal of dental research 18 17720860
2016 Circulating IL-18 Binding Protein (IL-18BP) and IL-18 as Dual Biomarkers of Total-Body Irradiation in Mice. Radiation research 16 27023262
2014 Effect of hydrodynamics-based delivery of IL-18BP fusion gene on rat experimental autoimmune myocarditis. Clinical and experimental medicine 15 24122347
2023 IL-18BP mediates the balance between protective and pathological immune responses to Toxoplasma gondii. Cell reports 14 36827187
2015 The effects of IL-18BP on mRNA expression of inflammatory cytokines and apoptotic genes in renal injury induced by infrarenal aortic occlusion. The Journal of surgical research 14 27083945
2017 Enhanced Expression of IL-18 and IL-18BP in Plasma of Patients with Eczema: Altered Expression of IL-18BP and IL-18 Receptor on Mast Cells. Mediators of inflammation 11 28839348
2025 Nanobody-engineered bispecific IL-18 mimetics drive antitumor immunity by engaging CD8+ T cell and evading IL-18BP in preclinical models. Molecular therapy : the journal of the American Society of Gene Therapy 10 40676834
2022 IL-18BP Alleviates Anxiety-Like Behavior Induced by Traumatic Stress via Inhibition of the IL-18R-NLRP3 Signaling Pathway in a Mouse Model of Hemorrhagic Shock and Resuscitation. Molecular neurobiology 10 36269543
2018 Remifentanil upregulates hepatic IL-18 binding protein (IL-18BP) expression through transcriptional control. Laboratory investigation; a journal of technical methods and pathology 8 30089853
2016 IL1R9 Is Evolutionarily Related to IL18BP and May Function as an IL-18 Receptor. Journal of immunology (Baltimore, Md. : 1950) 8 27881706
2023 Albumin-binding recombinant human IL-18BP ameliorates macrophage activation syndrome and atopic dermatitis via direct IL-18 inactivation. Cytokine 7 37918054
2018 Epigenetic regulation by CpG methylation splits strong from retarded IFNγ-induced IL-18BP in epithelial versus monocytic cells. Biochimica et biophysica acta. Gene regulatory mechanisms 7 29409936
2003 A monoclonal antibody specific for rat IL-18BP and its application in determining serum IL-18BP. Immunology letters 7 12505199
2022 Functional characterization of IL-18 receptor subunits, IL-18Rα and IL-18Rβ, and its natural inhibitor, IL-18 binding protein (IL-18BP) in rainbow trout Oncorhynchus mykiss. Developmental and comparative immunology 6 36496012
2003 Up-regulation of IL-18BP, but not IL-18 mRNA in rat liver by LPS. Cytokine 6 12788303
2023 Detection of Free Bioactive IL-18 and IL-18BP in Inflammatory Disorders. Methods in molecular biology (Clifton, N.J.) 5 37355553
2024 Interleukin-18 Binding Protein (IL-18BP): A Long Journey From Discovery to Clinical Application. Immune network 4 38455460
2022 IL-18BP Improves Early Graft Function and Survival in Lewis-Brown Norway Rat Orthotopic Liver Transplantation Model. Biomolecules 4 36551229
2023 Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 3 37774670
2024 IL-18BP Therapy Ameliorates Reproductive and Metabolic Phenotypes in a PCOS Mouse Model by Relieving Inflammation, Fibrosis and Endoplasmic Reticulum Stress. Reproductive sciences (Thousand Oaks, Calif.) 2 38977641
2024 IL-18 signaling is regulated by caspase 6/8 and IL-18BP in turbot (Scophthalmus maximus). International journal of biological macromolecules 2 39181350
2023 A small non-interface surface epitope in human IL18 mediates the dynamics and self-assembly of IL18-IL18BP heterodimers. Computational and structural biotechnology journal 2 37484491
2025 Interleukin-18 (IL-18) engineered for half-life extension and resistance to IL-18 binding protein (IL-18BP) to enhance anti-cancer therapeutic potential. Cytokine 1 40544635
2019 No IL-18BP? Avoid HAV. The Journal of experimental medicine 1 31243052
2011 [The study of IL-18 and IL-18BP balance in aplastic anemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 1 22339918
2010 Plasma IL-18 and IL-18BP are altered differently in reverse remodeling following aortic valve replacement. Scandinavian cardiovascular journal : SCJ 1 19961286
2025 Engineered Probiotics Secreting IL-18BP and Armed with Dual Single-Atom Catalysts for Synergistic Therapy in Ulcerative Colitis. ACS applied materials & interfaces 0 40890100
2025 The role of IL-18BP in alleviating anxiety-like behaviors after traumatic brain injury in rats by modulating astrocytic pyroptosis in amygdala. Brain injury 0 40995942
2024 Blood Interleukin-18 (IL-18) and IL-18 Binding Protein (IL-18BP) Levels Following Midline Laparotomy: A Prospective Randomized Study of Patients With Benign Disease and Patients With Cancer. Anticancer research 0 38677734
2013 [Effect of IL-18BP on Fractalkine chemokine expression in the kidney tissue of rats with renal fibrosis]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 0 24342215